<DOC>
	<DOCNO>NCT01049841</DOCNO>
	<brief_summary>The purpose study test safety effectiveness 2 drug , perifosine combination temsirolimus child solid tumor . Neither drug currently part standard treatment solid tumor child . Both drug test alone treat solid tumor child little success . There new insight give together , perifosine temsirolimus may work together stop growth solid tumor may also make shrink . The doctor want find effect ; good and/or bad , perifosine combination temsirolimus patient cancer . The doctor test four different dose schedule perifosine temsirolimus patient ask partake one dose schedule . The dose schedule lower enrol early study .</brief_summary>
	<brief_title>Perifosine With Temsirolimus Recurrent Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Any solid tumor fail standard therapy Patient must evidence tumor CT , MRI , MIBG scan , serum marker , tissue sampling . Age ≤ 21 year ( age ≤ 35 year biopsy proven medulloblastoma neuroblastoma ) Karnofsky/Lansky performance status ≥ 50 % ( Karnofsky score age &gt; 16 year Lansky score age ≤ 16 year ) ANC≥ 1000 least 24 hour GCSF Platelets ≥ 100K least one week platelet transfusion Hg≥ 8g/dL least one week PRBC transfusion AST ≤ 2 x upper limit normal ALT ≤ 2 x upper limit normal Total bilirubin ≤ 2.0 mg/dl Patients must cholesterol level &lt; 350 mg/dl triglyceride level &lt; 400 mg/dl temsirolimus induce hyperlipidemia . Serum creatinine ≤ 1.5 x upper limit normal age , calculate creatinine clearance nuclear GFR ≥ 70 ml/min/1.73 m2 . ≥ 3 week since last nonnitrosourea chemotherapy ≥ 6 week since last nitrosoureas ≥ 4 week since last RT Patients must agree practice adequate contraception . Females childbearing potential must negative serum BHCG pregnancy test document within 14 day prior registration . Females must breast feeding . Patients must able swallow tablet whole Patients participate phase I single agent perifosine study recurrent pediatric solid tumor experience DLT eligible participate study start ≥ 2 week since last dose perifosine Patients previously treat mTOR inhibitor still enroll trial long experience DLT single agent mTOR inhibitor trial Pregnancy Patients must uncontrolled active infection . HIVPositive patient receive combination antiretroviral therapy exclude study due possible retroviral drug interaction . HIV test require . Patients must take EIAEDs . If patient previously EIAEDs discontinue , patient must agent least 2 week prior registration . History known pulmonary hypertension history know pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>child</keyword>
	<keyword>perifosine</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>recurrent</keyword>
	<keyword>progressive</keyword>
	<keyword>09-124</keyword>
</DOC>